Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KMDA Stock Forecast 2025-2026
$6.63
Current Price
$391.64M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to KMDA Price Targets
+201.7%
To High Target of $20.00
+111.2%
To Median Target of $14.00
+65.9%
To Low Target of $11.00
KMDA Price Momentum
-4.5%
1 Week Change
+0.2%
1 Month Change
+25.1%
1 Year Change
+8.9%
Year-to-Date Change
-27.5%
From 52W High of $9.15
+39.9%
From 52W Low of $4.74
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Kamada (KMDA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on KMDA and similar high-potential opportunities.
Latest KMDA Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, KMDA has a bullish consensus with a median price target of $14.00 (ranging from $11.00 to $20.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $6.63, the median forecast implies a 111.2% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Andrew Fein at HC Wainwright & Co., suggesting a 65.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KMDA Analyst Ratings
3
Buy
0
Hold
0
Sell
KMDA Price Target Range
Low
$11.00
Average
$14.00
High
$20.00
Current: $6.63
Latest KMDA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KMDA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2025 | Benchmark | Robert Wasserman | Buy | Reiterates | $15.00 |
| Mar 21, 2025 | Benchmark | Robert Wasserman | Buy | Initiates | $15.00 |
| Mar 6, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Jul 3, 2024 | Stifel | Annabel Samimy | Buy | Initiates | $18.00 |
| May 9, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Mar 7, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Nov 14, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Aug 17, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| May 25, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Mar 16, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
| Feb 2, 2018 | Chardan Capital | Buy | Initiates | $7.00 | |
| Nov 13, 2015 | Jefferies | Buy | Maintains | $8.00 | |
| Jun 25, 2013 | Jefferies | Buy | Initiates | $0.00 | |
| Jun 25, 2013 | Morgan Stanley | Equal-Weight | Initiates | $0.00 | |
| Jun 25, 2013 | Oppenheimer | Outperform | Initiates | $0.00 |
Kamada Ltd. (KMDA) Competitors
The following stocks are similar to Kamada based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Kamada Ltd. (KMDA) Financial Data
Kamada Ltd. has a market capitalization of $391.64M with a P/E ratio of 23.7x. The company generates $167.24M in trailing twelve-month revenue with a 9.6% profit margin.
Revenue growth is +16.6% quarter-over-quarter, while maintaining an operating margin of +17.7% and return on equity of +6.4%.
Valuation Metrics
Market Cap
$391.64M
Enterprise Value
$310.30M
P/E Ratio
23.7x
PEG Ratio
21.4x
Price/Sales
2.3x
Growth & Margins
Revenue Growth (YoY)
+16.6%
Gross Margin
+47.1%
Operating Margin
+17.7%
Net Margin
+9.6%
EPS Growth
+67.6%
Financial Health
Cash/Price Ratio
+20.3%
Current Ratio
3.3x
Debt/Equity
4.4x
ROE
+6.4%
ROA
+4.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Kamada Ltd. (KMDA) Business Model
About Kamada Ltd.
What They Do
Biopharmaceutical company focused on plasma-derived therapies.
Business Model
Kamada Ltd. generates revenue by developing, producing, and marketing specialty plasma-derived protein therapeutics. The company focuses on innovative solutions for unmet clinical needs in immunology, respiratory diseases, and critical care, with a diverse product portfolio including treatments for rare conditions.
Additional Information
Kamada is headquartered in Israel and has a strong international distribution network, collaborating with multinational healthcare companies to enhance global access to its products. The company's emphasis on research and development supports its growth strategy and positions it as a key player in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
420
CEO
Country
Israel
IPO Year
2010
Website
www.kamada.comKamada Ltd. (KMDA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade
The mean of analysts' price targets for Kamada (KMDA) points to a 106.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
May 16, 2025
By Zacks Equity Research
Tale of the Tape
Is Kamada (KMDA) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
May 16, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Kamada Ltd. (NASDAQ: KMDA) will hold its Q1 2025 earnings conference call on May 14, 2025, at 8:30 AM ET, featuring CEO Amir London and CFO Chaime Orlev.
Why It Matters
The scheduled earnings call for Kamada Ltd. indicates upcoming financial performance insights, critical for assessing the company's health and potential investment risks or opportunities.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Kamada Ltd. (NASDAQ: KMDA) reported its financial results for Q1 2025, focusing on its specialty plasma-derived products for rare conditions. Further details on performance were not provided.
Why It Matters
Kamada Ltd.'s financial results may impact its stock performance, reflecting operational health and growth potential, particularly in the niche biopharmaceutical market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Kamada (KMDA) Q1 Earnings Match Estimates
10 days ago
Quick Summary
Kamada (KMDA) reported quarterly earnings of $0.07 per share, matching the Zacks Consensus Estimate and up from $0.04 per share year-over-year.
Why It Matters
Kamada's earnings meeting expectations and improving year-over-year signals stable growth, potentially boosting investor confidence and affecting stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Kamada's (KMDA) quarterly performance for March 2025 should be evaluated against Wall Street estimates and year-ago metrics for a comprehensive analysis.
Why It Matters
Kamada's quarterly performance relative to Wall Street estimates and previous year figures can signal growth potential or red flags, influencing investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Zacks utilizes its Zacks Rank system, focusing on earnings estimates and revisions, while also monitoring value, growth, and momentum trends to identify strong stock picks.
Why It Matters
The Zacks Rank system highlights stocks based on earnings estimates and revisions, providing investors with insights into potential high-performing stocks aligned with current market trends.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Analysts' price targets for Kamada (KMDA) suggest a 106.6% upside, supported by a consensus increase in earnings estimates, indicating potential stock growth.
Why It Matters
Analysts' price targets suggest significant upside for Kamada (KMDA), indicating potential growth. Consensus on raised earnings estimates further supports a positive outlook for the stock.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About KMDA Stock
What is Kamada Ltd.'s (KMDA) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Kamada Ltd. (KMDA) has a median price target of $14.00. The highest price target is $20.00 and the lowest is $11.00.
Is KMDA stock a good investment in 2025?
According to current analyst ratings, KMDA has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.63. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KMDA stock?
Wall Street analysts predict KMDA stock could reach $14.00 in the next 12 months. This represents a 111.2% increase from the current price of $6.63. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kamada Ltd.'s business model?
Kamada Ltd. generates revenue by developing, producing, and marketing specialty plasma-derived protein therapeutics. The company focuses on innovative solutions for unmet clinical needs in immunology, respiratory diseases, and critical care, with a diverse product portfolio including treatments for rare conditions.
What is the highest forecasted price for KMDA Kamada Ltd.?
The highest price target for KMDA is $20.00 from at , which represents a 201.7% increase from the current price of $6.63.
What is the lowest forecasted price for KMDA Kamada Ltd.?
The lowest price target for KMDA is $11.00 from Andrew Fein at HC Wainwright & Co., which represents a 65.9% increase from the current price of $6.63.
What is the overall KMDA consensus from analysts for Kamada Ltd.?
The overall analyst consensus for KMDA is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are KMDA stock price projections?
Stock price projections, including those for Kamada Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 8:45 AM UTC